Morgan Stanley’s Oruka Therapeutics ORKA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.27M | Sell |
76,360
-99,094
| -56% | -$6.6M | ﹤0.01% | 3964 |
|
|
2026
Q1 | $8.61M | Buy |
175,454
+53,256
| +44% | +$1.85M | ﹤0.01% | 3688 |
|
|
2025
Q4 | $3.7M | Sell |
122,198
-12,635
| -9% | -$352K | ﹤0.01% | 4403 |
|
|
2025
Q3 | $2.59M | Sell |
134,833
-73,495
| -35% | -$1.09M | ﹤0.01% | 4620 |
|
|
2025
Q2 | $2.34M | Sell |
208,328
-319,463
| -61% | -$3.33M | ﹤0.01% | 4601 |
|
|
2025
Q1 | $5.42M | Buy |
527,791
+121,793
| +30% | +$1.52M | ﹤0.01% | 3860 |
|
|
2024
Q4 | $7.87M | Buy |
405,998
+337,865
| +496% | +$8.24M | ﹤0.01% | 3604 |
|
|
2024
Q3 | $1.67M | Buy |
68,133
+13,966
| +26% | +$486K | ﹤0.01% | 4752 |
|
|
2024
Q2 | $2.49M | Buy |
+54,167
| New | +$2.16M | ﹤0.01% | 4412 |
|
|
2023
Q2 | – | Sell |
-25
| Closed | -$597 | – | 7709 |
|
|
2023
Q1 | $597 | Buy |
+25
| New | +$659 | ﹤0.01% | 7414 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 8149 |
|
|
2021
Q4 | – | Sell |
-1
| Closed | -$30 | – | 8137 |
|
|
2021
Q3 | $0 | Buy |
+1
| New | +$37 | ﹤0.01% | 8045 |
|
|
2021
Q2 | – | Sell |
-3,395
| Closed | -$149K | – | 7814 |
|
|
2021
Q1 | $149K | Buy |
3,395
+3,072
| +951% | +$161K | ﹤0.01% | 5816 |
|
|
2020
Q4 | $16K | Buy |
+323
| New | +$16.1K | ﹤0.01% | 6506 |
|
|
2020
Q1 | – | Sell |
-9
| Closed | -$489 | – | 6733 |
|
|
2019
Q4 | $1K | Hold |
9
| – | – | ﹤0.01% | 6599 |
|
|
2019
Q3 | $1K | Hold |
9
| – | – | ﹤0.01% | 6585 |
|
|
2019
Q2 | $1K | Hold |
9
| – | – | ﹤0.01% | 6581 |
|
|
2019
Q1 | $1K | Hold |
9
| – | – | ﹤0.01% | 6543 |
|
|
2018
Q4 | $1K | Hold |
9
| – | – | ﹤0.01% | 6529 |
|
|
2018
Q3 | $1K | Hold |
9
| – | – | ﹤0.01% | 6659 |
|
|
2018
Q2 | $1K | Buy |
9
+8
| +800% | +$939 | ﹤0.01% | 6613 |
|
|
2018
Q1 | $0 | Buy |
+1
| New | +$268 | ﹤0.01% | 6713 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6669 |
|
|
2017
Q3 | – | Sell |
-1
| Closed | -$356 | – | 6629 |
|
|
2017
Q2 | $1K | Buy |
+1
| New | +$521 | ﹤0.01% | 6527 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6621 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6571 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6743 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 6767 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 6673 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6686 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 6672 |
|
|
2014
Q2 | – | Sell |
-57
| Closed | -$133K | – | 6611 |
|
|
2014
Q1 | $160K | Buy |
57
+20
| +54% | +$58.4K | ﹤0.01% | 5217 |
|
|
2013
Q4 | $95K | Buy |
+37
| New | +$85.4K | ﹤0.01% | 5366 |
|
Other funds holding ORKA
VA
FFM
RI
PBA
DTC
Morgan Stanley's ORKA Position: Q2 2026 in Review
Morgan Stanley reduced its Oruka Therapeutics (ORKA) stake by 56% in Q2 2026, selling an estimated $6.6M and leaving 76,360 shares worth $7.27M. The position accounts for ﹤0.01% of the portfolio, ranked #3964.
Morgan Stanley first reported a position in ORKA in Q4 2013 and has held it in 24 quarters since. The position peaked at $8.61M in Q1 2026. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.
- Morgan Stanley held 76,360 shares of Oruka Therapeutics worth $7.27M as of Q2 2026.
- Morgan Stanley sold 99,094 Oruka Therapeutics shares in Q2 2026, an estimated $6.6M.
- Oruka Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3964 holding.
- Morgan Stanley first reported a position in Oruka Therapeutics in Q4 2013 and has held it in 24 quarters since.
- Morgan Stanley's Oruka Therapeutics position peaked at $8.61M in Q1 2026.
- 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.